+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures, and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. Boehringer is headquartered in Ingelheim am Rhein,Rhineland-Palatinate, Germany.

Boehringer Ingelheim International GmbH Key Recent Developments

  • Apr 17, 2025: Boehringer Ingelheim announces succession Chairmen Shareholders’ Committee and Board of Managing Directors?
  • Apr 16, 2025: Boehringer and Cue Biopharma to develop autoimmune therapies
  • Apr 03, 2025: Boehringer Ingelheim Strengthens Antibody-Drug Conjugate Portfolio With New NBE Therapeutics R&D Center in Basel
  • Apr 02, 2025: Boehringer Ingelheim Reaches More Patients in 2024 and Prepares New Medicine Launches

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with the analyst’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Boehringer Ingelheim International GmbH - Key Facts
  • Boehringer Ingelheim International GmbH - Key Employees
  • Boehringer Ingelheim International GmbH - Key Employee Biographies
  • Boehringer Ingelheim International GmbH - Major Products and Services
  • Boehringer Ingelheim International GmbH - History
  • Boehringer Ingelheim International GmbH - Company Statement
  • Boehringer Ingelheim International GmbH - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Boehringer Ingelheim International GmbH - Business Description
  • Business Segment: Animal Health
  • Overview
  • Performance
  • Business Segment: Human Pharmaceuticals
  • Overview
  • Performance
  • Business Segment: Other Sales
  • Performance
  • Geographical Segment: Americas
  • Performance
  • Geographical Segment: Asia/Australia/Africa
  • Performance
  • Geographical Segment: Europe
  • Performance
  • R&D Overview
  • Boehringer Ingelheim International GmbH - Corporate Strategy
  • Boehringer Ingelheim International GmbH - SWOT Analysis
  • SWOT Analysis - Overview
  • Boehringer Ingelheim International GmbH - Strengths
  • Boehringer Ingelheim International GmbH - Weaknesses
  • Boehringer Ingelheim International GmbH - Opportunities
  • Boehringer Ingelheim International GmbH - Threats
  • Boehringer Ingelheim International GmbH - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Boehringer Ingelheim International GmbH, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Apr 17, 2025: Boehringer Ingelheim announces succession Chairmen Shareholders’ Committee and Board of Managing Directors?
  • Apr 16, 2025: Boehringer and Cue Biopharma to develop autoimmune therapies
  • Apr 03, 2025: Boehringer Ingelheim Strengthens Antibody-Drug Conjugate Portfolio With New NBE Therapeutics R&D Center in Basel
  • Apr 02, 2025: Boehringer Ingelheim Reaches More Patients in 2024 and Prepares New Medicine Launches
  • Mar 11, 2025: Boehringer Ingelheim, Cognizant Launch Unified Cloud Platform
  • Mar 11, 2025: Boehringer Ingelheim Joins Hands With Veeva to Launch ''One Medicine Platform''
  • Mar 11, 2025: Boehringer Ingelheim Teams Up With Veeva to Launch ‘One Medicine Platform’
  • Mar 04, 2025: Boehringer Ingelheim Enhances Biopharmaceutical Contract Manufacturing Services in China
  • Jan 10, 2025: Synaffix secures ADC deals with Boehringer and Mitsubishi Tanabe
  • Nov 19, 2024: Boehringer’s Focus On Health Equity Drives Significant Upgrade in Access to Medicine Index Ranking
Section 5 - Appendix
  • Methodology
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Boehringer Ingelheim International GmbH, Key Facts
  • Boehringer Ingelheim International GmbH, Key Employees
  • Boehringer Ingelheim International GmbH, Key Employee Biographies
  • Boehringer Ingelheim International GmbH, Major Products and Services
  • Boehringer Ingelheim International GmbH, History
  • Boehringer Ingelheim International GmbH, Subsidiaries
  • Boehringer Ingelheim International GmbH, Key Competitors
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Boehringer Ingelheim International GmbH, Recent Deals Summary
List of Figures
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Pfizer Inc
  • Novartis AG
  • GSK plc
  • Fresenius SE & Co KGaA
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • AbbVie Inc